Optical Genome Mapping Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Consumables v/s Instruments), By Application (Genome Assembly, Structural Variation Detection, Microbial Strain Typing, Haplotype Phasing, Others), By End User (Research and Academic Institutions, Biotechnology & Pharmaceutical Companies, Clinical Laboratories, Others) By Region & Competition, 2021-2031F

January 2026 | 180 pages | ID: O771CFE4B3F6EN
TechSci Research

Abstracts

The Global Optical Genome Mapping Market is projected to expand from USD 0.27 Billion in 2025 to USD 0.97 Billion by 2031, registering a CAGR of 23.76%. As a non-sequencing technology, optical genome mapping analyzes ultra-long DNA molecules to detect structural variations with a resolution exceeding traditional cytogenetic techniques. The market is primarily driven by the rising clinical need for accurate diagnosis of hematologic malignancies and a strategic shift within laboratories to merge various legacy workflows into a unified digital assay. These drivers enable medical facilities to generate comprehensive genomic profiles more efficiently, improving patient care and shortening the time required for critical diagnostic results.

Despite its evident clinical benefits, the substantial initial capital investment for equipment and the considerable bioinformatic resources needed for analysis pose significant hurdles to adoption in smaller pathology centers. Data presented by the European Hematology Association in 2024 revealed that clinical research using optical genome mapping improved risk stratification in roughly 18 percent of myeloid neoplasm cases compared to standard protocols. While this figure highlights the platform's diagnostic advantages, it also emphasizes the sophisticated data interpretation requirements that could slow down broader market growth.

Market Driver

Expanding applications in cancer diagnostics and oncology research, particularly for hematological malignancies, are fundamentally transforming the Global Optical Genome Mapping Market. As clinicians increasingly demand detailed genomic profiles to inform precision medicine, extending the capabilities of optical genome mapping beyond mere agreement with legacy techniques has become a key objective. The technology is rapidly being adopted for its capacity to identify hidden structural variants often overlooked by next-generation sequencing, providing vital prognostic information for complex cases of leukemia and lymphoma. According to a study referenced by the National Library of Medicine in April 2025, optical genome mapping detected additional clinically significant Tier 1 variants in 15 percent of hematological malignancy cases compared to standard cytogenetic evaluations, confirming its critical role in enhancing patient management.

A second major factor propelling market momentum is the systematic replacement of traditional cytogenetic methods like karyotyping and fluorescence in situ hybridization (FISH). Laboratories are actively merging fragmented workflows into this single, high-resolution digital assay to boost operational efficiency and alleviate the cost pressures of labor-intensive manual techniques. This shift from analog to digital cytogenetics is underscored by the rising demand for testing consumables; Bionano Genomics reported in January 2025 the sale of 8,058 nanochannel array flowcells for the fourth quarter of 2024. Furthermore, the company's preliminary report from the same month indicated that the global installed base had grown to 371 optical genome mapping systems, reflecting the increasing operational transition toward this platform.

Market Challenge

The significant capital investment required for instrumentation, coupled with the extensive bioinformatic resources necessary for data analysis, serves as a major obstacle to the widespread uptake of optical genome mapping. Many diagnostic laboratories, particularly smaller community centers, face strict budget limitations that make it difficult to justify the high upfront hardware costs and the continuous expense of specialized digital infrastructure. Consequently, this financial strain limits the technology's availability primarily to well-resourced academic institutions and large reference laboratories, hindering the market from achieving commercial scale based on high sample volumes.

The effect of these economic and technical challenges is reflected in recent adoption figures. Survey data from the College of American Pathologists in 2024 revealed that only 9.4 percent of participating laboratories had successfully integrated optical genome mapping. This low rate of utilization demonstrates that the market remains highly fragmented, with most pathology providers unable to incorporate the platform into their regular workflows. As a result, high entry barriers directly constrain the potential revenue expansion of the global market by relegating the technology to a niche role rather than enabling its progression into routine clinical practice.

Market Trends

A pivotal trend is the application of optical genome mapping to resolve undiagnosed rare genetic diseases, addressing the shortcomings of standard-of-care methods for constitutional disorders. Clinicians are increasingly adopting this technology to uncover pathogenic structural variants in patients who remain without a diagnosis following exome or genome sequencing, thereby concluding distinct diagnostic odysseys. This transition toward utilizing the platform as a primary instrument for germline analysis is extending its reach beyond oncology into medical genetics departments, where detecting cryptic variants is essential. According to the 'Current and Future Utilization of Optical Genome Mapping' report cited by the National Library of Medicine in November 2025, survey data showed that 108 laboratories intend to adopt the technology clinically within 24 months, largely driven by its utility in constitutional and germline analysis.

Simultaneously, the introduction of optical genome mapping into prenatal and postnatal reproductive testing is creating a new commercial pathway for the market. Laboratories are validating the platform to identify balanced translocations and complex chromosomal rearrangements in fetal samples and preimplantation embryos, offering resolution superior to that of chromosomal microarrays. This capability is vital for enhancing in-vitro fertilization success rates and providing precise risk assessments for recurrent pregnancy loss, fueling growth in a segment distinct from cancer diagnostics. The increasing scientific support for this application is highlighted by Bionano Genomics' 'Fourth Quarter and Full-Year 2024 Results' from March 2025, which noted that the total number of optical genome mapping publications rose to 336 in 2024, a 19 percent annual increase characterized by significant research growth in prenatal and postnatal genetic disorders.

Key Market Players

• Bionano Genomics, Inc.
• Nucleome Informatics Private Limited
• Nabsys, Inc.
• PerkinElmer, Inc.
• SourceBio International Limited
• MedGenome Labs Private Limited
• Cerba HealthCare
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies plc

Report Scope

In this report, the Global Optical Genome Mapping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Optical Genome Mapping Market, By Product
• Consumables v/s Instruments
• Optical Genome Mapping Market, By Application
• Genome Assembly
• Structural Variation Detection
• Microbial Strain Typing
• Haplotype Phasing
• Others
• Optical Genome Mapping Market, By End User
• Research and Academic Institutions
• Biotechnology & Pharmaceutical Companies
• Clinical Laboratories
• Others
• Optical Genome Mapping Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optical Genome Mapping Market.

Available Customizations:

Global Optical Genome Mapping Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL OPTICAL GENOME MAPPING MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Product (Consumables v/s Instruments)
  5.2.2. By Application (Genome Assembly, Structural Variation Detection, Microbial Strain Typing, Haplotype Phasing, Others)
  5.2.3. By End User (Research and Academic Institutions, Biotechnology & Pharmaceutical Companies, Clinical Laboratories, Others)
  5.2.4. By Region
  5.2.5. By Company (2025)
5.3. Market Map

6. NORTH AMERICA OPTICAL GENOME MAPPING MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Product
  6.2.2. By Application
  6.2.3. By End User
  6.2.4. By Country
6.3. North America: Country Analysis
  6.3.1. United States Optical Genome Mapping Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Product
      6.3.1.2.2. By Application
      6.3.1.2.3. By End User
  6.3.2. Canada Optical Genome Mapping Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Product
      6.3.2.2.2. By Application
      6.3.2.2.3. By End User
  6.3.3. Mexico Optical Genome Mapping Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Product
      6.3.3.2.2. By Application
      6.3.3.2.3. By End User

7. EUROPE OPTICAL GENOME MAPPING MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Product
  7.2.2. By Application
  7.2.3. By End User
  7.2.4. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Optical Genome Mapping Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Product
      7.3.1.2.2. By Application
      7.3.1.2.3. By End User
  7.3.2. France Optical Genome Mapping Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Product
      7.3.2.2.2. By Application
      7.3.2.2.3. By End User
  7.3.3. United Kingdom Optical Genome Mapping Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Product
      7.3.3.2.2. By Application
      7.3.3.2.3. By End User
  7.3.4. Italy Optical Genome Mapping Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Product
      7.3.4.2.2. By Application
      7.3.4.2.3. By End User
  7.3.5. Spain Optical Genome Mapping Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Product
      7.3.5.2.2. By Application
      7.3.5.2.3. By End User

8. ASIA PACIFIC OPTICAL GENOME MAPPING MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Product
  8.2.2. By Application
  8.2.3. By End User
  8.2.4. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Optical Genome Mapping Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Product
      8.3.1.2.2. By Application
      8.3.1.2.3. By End User
  8.3.2. India Optical Genome Mapping Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Product
      8.3.2.2.2. By Application
      8.3.2.2.3. By End User
  8.3.3. Japan Optical Genome Mapping Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Product
      8.3.3.2.2. By Application
      8.3.3.2.3. By End User
  8.3.4. South Korea Optical Genome Mapping Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Product
      8.3.4.2.2. By Application
      8.3.4.2.3. By End User
  8.3.5. Australia Optical Genome Mapping Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Product
      8.3.5.2.2. By Application
      8.3.5.2.3. By End User

9. MIDDLE EAST & AFRICA OPTICAL GENOME MAPPING MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Product
  9.2.2. By Application
  9.2.3. By End User
  9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Optical Genome Mapping Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Product
      9.3.1.2.2. By Application
      9.3.1.2.3. By End User
  9.3.2. UAE Optical Genome Mapping Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Product
      9.3.2.2.2. By Application
      9.3.2.2.3. By End User
  9.3.3. South Africa Optical Genome Mapping Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Product
      9.3.3.2.2. By Application
      9.3.3.2.3. By End User

10. SOUTH AMERICA OPTICAL GENOME MAPPING MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Product
  10.2.2. By Application
  10.2.3. By End User
  10.2.4. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Optical Genome Mapping Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Product
      10.3.1.2.2. By Application
      10.3.1.2.3. By End User
  10.3.2. Colombia Optical Genome Mapping Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Product
      10.3.2.2.2. By Application
      10.3.2.2.3. By End User
  10.3.3. Argentina Optical Genome Mapping Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Product
      10.3.3.2.2. By Application
      10.3.3.2.3. By End User

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL OPTICAL GENOME MAPPING MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Bionano Genomics, Inc.
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Nucleome Informatics Private Limited
15.3. Nabsys, Inc.
15.4. PerkinElmer, Inc.
15.5. SourceBio International Limited
15.6. MedGenome Labs Private Limited
15.7. Cerba HealthCare
15.8. Illumina, Inc.
15.9. Thermo Fisher Scientific Inc.
15.10. Oxford Nanopore Technologies plc

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER